Afrezza
Pharma

FDA signs off on pediatric expansion for MannKind's Afrezza

The FDA has signed off on an expansion for MannKind's inhaled insulin Afrezza to be used by adolescents and children with Type 1 or Type 2 diabetes.
Kevin Dunleavy May 29, 2026 12:55pm
Food and Drug Administration

Regulatory tracker: Tremfya, Venclyxto secure label expansions

May 29, 2026 10:12am
Eliminating KRAS Why targeted protein degraders could redefinewhatspossible in cancer

Eliminating KRAS: How degraders could redefine cancer care

Brought to you by ASTELLAS
china chinese Asia

More biotech hawkishness, Pfizer’s $10B deal—Fierce Pharma Asia

May 29, 2026 8:30am
Real-World Evidence in the AI Era What You Can Unlock Depends on What You Build On

RWE in the AI Era: What You Unlock Depends on What You Build On

Brought to you by Flatiron Health
Pills medicine in Dollar sign shape on blue background

Brand-name drug prices climb with age in US, fall abroad: report

May 29, 2026 8:10am
More News

Dizal takes on J&J with first-line win in EGFR lung cancer type

May 29, 2026 8:00am

Pharma urged to adapt support to changing patient populations

May 29, 2026 6:45am

Philips adds a spoonful of Disney sugar to ease MRI anxieties

May 29, 2026 5:25am

AZ gains on Merck with 2nd bladder cancer nod for Imfinzi

May 28, 2026 4:39pm